Cargando…
EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after resistance to alectinib. A right lower lo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088238/ https://www.ncbi.nlm.nih.gov/pubmed/33906872 http://dx.doi.org/10.1136/bcr-2020-240295 |
_version_ | 1783686811924561920 |
---|---|
author | Matsuda, Hironari Hara, Munechika Iwakami, Shin-Ichiro Takahashi, Kazuhisa |
author_facet | Matsuda, Hironari Hara, Munechika Iwakami, Shin-Ichiro Takahashi, Kazuhisa |
author_sort | Matsuda, Hironari |
collection | PubMed |
description | This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after resistance to alectinib. A right lower lobectomy based on a diagnosis of lung adenocarcinoma was performed on a 77-year-old Japanese woman. After 7 months of surgical resection, a mass in the right calf was observed. A fine-needle aspiration biopsy from the mass was performed and the mass was diagnosed as metastatic adenocarcinoma harbouring EML4-ALK rearrangement. Alectinib was administered for 10 months. Then, administration of lorlatinib, an ALK tyrosine kinase inhibitor classified as third generation, was initiated after resistance to treatment with alectinib. After starting treatment with lorlatinib, the gastrocnemius tumour diminished and has maintained a stable condition. Our case suggests that EML4-ALK positive lung adenocarcinoma is treatable with lorlatinib after resistance to treatment with alectinib. |
format | Online Article Text |
id | pubmed-8088238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80882382021-05-14 EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib Matsuda, Hironari Hara, Munechika Iwakami, Shin-Ichiro Takahashi, Kazuhisa BMJ Case Rep Case Report This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after resistance to alectinib. A right lower lobectomy based on a diagnosis of lung adenocarcinoma was performed on a 77-year-old Japanese woman. After 7 months of surgical resection, a mass in the right calf was observed. A fine-needle aspiration biopsy from the mass was performed and the mass was diagnosed as metastatic adenocarcinoma harbouring EML4-ALK rearrangement. Alectinib was administered for 10 months. Then, administration of lorlatinib, an ALK tyrosine kinase inhibitor classified as third generation, was initiated after resistance to treatment with alectinib. After starting treatment with lorlatinib, the gastrocnemius tumour diminished and has maintained a stable condition. Our case suggests that EML4-ALK positive lung adenocarcinoma is treatable with lorlatinib after resistance to treatment with alectinib. BMJ Publishing Group 2021-04-27 /pmc/articles/PMC8088238/ /pubmed/33906872 http://dx.doi.org/10.1136/bcr-2020-240295 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Matsuda, Hironari Hara, Munechika Iwakami, Shin-Ichiro Takahashi, Kazuhisa EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
title | EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
title_full | EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
title_fullStr | EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
title_full_unstemmed | EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
title_short | EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
title_sort | eml4-alk positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088238/ https://www.ncbi.nlm.nih.gov/pubmed/33906872 http://dx.doi.org/10.1136/bcr-2020-240295 |
work_keys_str_mv | AT matsudahironari eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib AT haramunechika eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib AT iwakamishinichiro eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib AT takahashikazuhisa eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib |